Degarelix

Degarelix is a synthetic peptidic gonadotropin-releasing hormone (GnRH) receptor antagonist used for the treatment of advanced hormone-sensitive prostate cancer. It rapidly reduces testosterone to castrate levels without initial testosterone surge seen with GnRH agonists. Mediocon Inc supplies pharmaceutical-grade Degarelix meeting IP, BP, EP, and USP standards.

Key Features

• Analgesic, antipyretic & anti-inflammatory
• USP/BP/IP compliant quality
• Widely used in cardiovascular therapy
• Suitable for tablet and effervescent formulations

Applications

• Advanced hormone-sensitive prostate cancer
• Androgen deprivation therapy (ADT)
• Pre-surgical testosterone reduction
• Prostate cancer clinical research

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings